Compare Vanguard Value Index Fund ETF (VTV) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Value Index Fund ETF vs Zimmer Biomet Holdings Inc — how do they compare? Vanguard Value Index Fund ETF trades at $223.92, while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $17.97B). The key difference: Zimmer Biomet Holdings Inc pays a 1.02% dividend while Vanguard Value Index Fund ETF pays none, and Vanguard Value Index Fund ETF is trading nearer its 52-week high, Zimmer Biomet Holdings Inc nearer its low. Which is the better fit depends on your goals.
| VTV | ZBH | |
|---|---|---|
52-Week High | $227.51 | $104.26 |
52-Week Low | $182.86 | $79.58 |
Market Cap | — | $17.97B |
Sector | — | Health |
Enterprise Value | — | $25.04B |
Dividend Yield | — | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VTV, the Vanguard Value ETF, trades at $224.64, down 0.8% on the day, with technical indicators showing a neutral overall signal amid mixed moving average and oscillator readings. The fund's value-focused strategy has outperformed growth counterparts in 2026, attracting institutional inflows, though key financial ratios are not individually disclosed for the ETF. A dividend of $1.08 is scheduled for June 2026.
The outlook for VTV is supported by the ongoing rotation into value stocks, with media highlighting its 2026 strength versus growth ETFs. Risks include potential underperformance if growth resumes leadership and fee-related long-term tracking differences noted in analysis. The neutral technical stance suggests near-term consolidation around current levels.
ZBH trades at $94.22, down 3.93% on the day, with a bearish technical signal but oversold RSI readings. Recent earnings beats and raised 2026 guidance support fundamentals, with revenue growth and strong gross margins. Leadership promotions aim to accelerate commercial transformation, while cash flow trends show operational strength.
The stock offers upside to the $104.88 consensus target, but faces headwinds from debt levels and competitive pressures. Near-term support at $92 is critical; a hold rating aligns with mixed analyst views. Earnings execution and procedure demand growth are key catalysts for valuation expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
